Metraipolis › archive › dc_d9567ccc03ca

Cost-utility analysis of eptinezumab for migraine prevention in Taiwan — Europe PMC PMID:41455879

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41455879
DOI
10.1186/s13561-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-11-07T08:57:48.327Z
SHA-256 of the archived text
262d735a6b24bf60ecd522d3e4ddf853ddaa22534b896e9bdde7bcaae5448597
Stable URL of this page
https://metraipolis.com/documento/dc_d9567ccc03ca

How to cite

Cost-utility analysis of eptinezumab for migraine prevention in Taiwan — Europe PMC PMID:41455879 — Europe PMC (en), https://europepmc.org/article/MED/41455879 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d9567ccc03ca (Metraipolis archive dc_d9567ccc03ca, sha256 262d735a6b24bf60ecd522d3e4ddf853ddaa22534b896e9bdde7bcaae5448597)
BibTeX
@misc{dcd9567ccc03ca,
  title = {Cost-utility analysis of eptinezumab for migraine prevention in Taiwan — Europe PMC PMID:41455879},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41455879},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d9567ccc03ca; sha256 262d735a6b24bf60ecd522d3e4ddf853ddaa22534b896e9bdde7bcaae5448597},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41455879. Agents can read the archived copy with the MCP tool read_document.